Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

Merilog is a rapid-acting human insulin analog designed to reduce spikes ... This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter multiple-dose vial ...

The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood ... s 3-milliliter single-patient-use prefilled pen and a 10-milliliter multiple-dose vial.

Q: I saw an advertisement in a magazine for a needle-free insulin pen. Can you tell me more about how this works and is it ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...

FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With ... Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval.

Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting insulin biosimilars approved by the FDA in 2021. Merilog, a rapid-acting human insulin analog, is the first ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...